References
- Alter H J. Post transfusion hepatitis: clinical features, risk, and donor testing. Infection, Immunity and Blood Transfusions, L F Barker, R Y Dood. Allan R. Liss, New York 1985; 47–61
- Siest G, Schiele F, Galteau M-M, Panek E, Steinmetz J, Fagnani F, Geugen R. Aspartate aminotransferase and alaninc aminotransferase activities in plasma: statistical distributions, individual variations, and reference values. Clin Chem 1975; 21: 1077–87
- Briere R O. Serum ALT levels. Effect of sex, race, and obesity on unit rejection rate. Transfusion 1988; 28: 392–3
- WejstÅl R, Hansson G, Lindholm A, Norkrans G. Persistent alanine aminotransferase elevation in healthy Swedish blood donors—mainly caused by obesity. Vox Sang 1988; 55: 152–6
- Robinson D, Whitchead T P. Effect of body mass and other factors on serum liver enzyme levels in men attending for well population screening. Ann Clin Biochem 1989; 26: 393–400
- Hetland G, Skaug K, Larsen J, Mæeland A, Strømme J H, Størvold G. Prevalence of anti-HCV in Norwegian blood donors with anti-HBc or increased ALT levels. Transfusion 1990; 30: 776–9
- Kuo G, Choo O-L, Alter H J, Gitnik G L, Dedeker A G, Purcell R H, Miyamura T, Dienstag J L, Alter M J, Stevens C E, Tegtmeier G E, Bonino F, Colombo M, Lee W-S, Kuo C, Berger K, Schuster J R, Overby L R, Bradley D W, Houghton M. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362–4
- Committee on enzymes, the Scandinavian Society for Clinical Chemistry and Clinical Physiology. Recommended methods for the determination of four enzymes in blood. Scand J Clin Lab Invest 1974; 33: 291–306
- Nomura F, Ohnishi K, Satomura Y, Ohtsuki T, Fukunaga K, Honda M, Ema M, Tohyama T, Sugita S, Saito M, Iida S, Okuda K. Liver function in moderate obesity—study in 534 moderately obese subjects among 4613 male company employees. Int J Obesity 1986; 10: 349–54